DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
FANCD2 maintains replication fork stability during misincorporation of the DNA demethylation products 5-hydroxymethyl-2’-deoxycytidine and 5-hydroxymethyl-2’-deoxyuridine
Fanconi anemia (FA) is a rare hereditary disorder caused by mutations in any one of the FANC genes. FA cells are mainly characterized by extreme hypersensitivity to interstrand crosslink (ICL) agents. Additionally, the FA proteins play a crucial role in concert with homologous recombination (HR) factors to protect stalled replication forks. Here, we report that the 5-methyl-2’-deoxycytidine (5mdC) demethylation (pathway) intermediate 5-hydroxymethyl-2’-deoxycytidine (5hmdC) and its deamination product 5-hydroxymethyl-2’-deoxyuridine (5hmdU) elicit a DNA damage response, chromosome aberrations, replication fork impairment and cell viability loss in the absence of FANCD2. Interestingly, replication fork instability by 5hmdC or 5hmdU was associated to the presence of Poly(ADP-ribose) polymerase 1 (PARP1) on chromatin, being both phenotypes exacerbated by olaparib treatment. Remarkably, Parp1 cells did not show any replication fork defects or sensitivity to 5hmdC or 5hmdU, suggesting that retained PARP1 at base excision repair (BER) intermediates accounts for the observed replication fork defects upon 5hmdC or 5hmdU incorporation in the absence of FANCD2. We therefore conclude that 5hmdC is deaminated in vivo to 5hmdU, whose fixation by PARP1 during BER, hinders replication fork progression and contributes to genomic instability in FA cells., The eHAP cell line were a generous gift from Dr. G. Crossan (MRC-LMB, Cambridge). DT40, NV012 and HSC72 cell lines were kindly provided by K.J. Patel (MRC WIMM, Oxford), and the MDA-MB-231, MDA-MB-436 and DLD1 BRCA2−/− were a gift from Dr. Pablo Huertas and Dr. Andrés Aguilera (CABIMER, Sevilla) respectively. We are in debt to Dr. J.A. Pérez-Simón (IBIS, Seville) for providing hosting and helpful advice. IVR´s lab is funded by MCIN/AEI/ 10.13039/501100011033, grant 18.06.03.3073 (RTI2018-100692-B-100), Consejerías de Salud, y de Economía y Conocimiento de la Junta de Andalucía, grants number PI-0005-2018, and 18.06.03.2404 (P18-RT-1271), Universidad de Sevilla “Programa Operativo FEDER Andalucía 2014–2020”, grant number 18.06.03.2319 (US-1381081), and by “ERDF A way of making Europe”. IVR is a recipient of Ramón y Cajal Contracts RYC2015-18670. SK lab was supported by ERC-2016-AdG/742654 grant.